Develops oncolytic virus therapies that infect and kill tumor cells while triggering an immune response against cancer.
Develops oncolytic virus therapies that infect and kill tumor cells while triggering an immune response against cancer.
Has no approved product, so it earns nothing from sales and pays for development by selling shares and other capital raises. Everything rests on RP1, an engineered herpes virus injected into tumours to kill cancer cells and prompt an immune response, studied alongside nivolumab in melanoma.
Moat: narrow (IP / patents, process know-how). Proprietary herpes-virus-based oncolytic platform engineered to boost anti-tumor immune response.
Headquarters: Woburn, Massachusetts, US · Founded: 2015 · Employees: 465
Size Replimune (REPL) is a United States Health Care company (Biotechnology) with a market value of $1.88B, the 1808th largest of 3,085 United States companies the cockpit tracks. Shares closed at $19.81 on 18 Nov 2026.
Performance Over six months the shares gained 321.5%, against -4.7% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 19 in its peer set.
Short interest Short interest is 26.0% of the free float (30 Oct 2026).
Next results Next results expected around 2 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$6.57M | -$6.53M | -$3.50M | -$2.65M | -$2.45M |
| EBITDA | -$265M | -$315M | -$260M | -$234M | -$178M |
| Net income | -$271M | -$314M | -$247M | -$216M | -$174M |
| Free cash flow | -$246M | -$285M | -$199M | -$191M | -$130M |
| Capital expenditure | $223,000 | $4.22M | $6.69M | $5.66M | $2.27M |
| Total debt | $127M | $112M | $76.2M | $75.9M | $60.8M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Replimune REPL | $1.88B | +321% | n/a | n/a | n/a | n/a |
| Amgen AMGN | $240B | +34% | +9% | 36% | 7.2× | 1.6% |
| Merck & MRK | $340B | +23% | +5% | 18% | 5.7× | 8.3% |
| Candel Therapeutics CADL | $417M | -31% | n/a | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | REPL | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +73.5% | -6.2% | highest of 20 |
| 6-month return | +321.5% | -4.7% | highest of 19 |
| Distance from 52-week high | -15.8% | -34.3% | 3rd highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Replimune REPL | United States | $1.88B | +321% | n/a | n/a | n/a | n/a | n/a |
| BioCryst Pharmaceuticals BCRX | United States | $1.88B | -16% | +60% | 42% | 2.4× | -11.0% | +117.9% |
| Septerna SEPN | United States | $1.88B | +41% | +337% | -76% | 14.7× | n/a | n/a |
| First Tracks Biotherapeutics TRAX | United States | $1.87B | +175% | n/a | n/a | n/a | n/a | n/a |
| Shenzhen Kangtai Biological Products 300601.SZ | China | $1.86B | -20% | -9% | 6% | 4.9× | 22.7% | +3.4% |
| Sinocelltech 688520.SS | China | $1.90B | -35% | -40% | -75% | 13.6× | n/a | n/a |
| Vera Therapeutics VERA | United States | $1.85B | -26% | n/a | -4,160% | 149.9× | n/a | n/a |
| Maravai Lifesciences MRVI | United States | $1.92B | +101% | +11% | -17% | 10.2× | n/a | n/a |
| Trevi Therapeutics TRVI | United States | $1.93B | -3% | n/a | n/a | n/a | n/a | n/a |
| Hemab Therapeutics COAG | United States | $1.83B | +48% | n/a | n/a | n/a | n/a | n/a |
| Lycia Therapeutics LYCA | United States | $1.81B | n/a | -55% | -593% | n/a | n/a | n/a |
| Zenas BioPharma ZBIO | United States | $1.79B | +35% | -27% | -2,748% | 146.1× | n/a | n/a |
| Immunome IMNM | United States | $1.98B | -22% | -100% | n/a | n/a | n/a | n/a |
| GemPharmatech 688046.SS | China | $1.78B | +39% | +25% | 22% | 11.7× | 33.0% | +24.8% |
| Recursion Pharmaceuticals RXRX | United States | $1.76B | -5% | +56% | -725% | 18.8× | n/a | n/a |
| Stoke Therapeutics STOK | United States | $1.75B | -12% | -86% | -913% | 50.6× | n/a | n/a |
| Aurinia Pharmaceuticals AUPH | United States | $2.03B | -5% | +21% | 45% | 5.0× | 3.5% | +41.4% |
| Evopoint Biosciences 688837.SS | China | $2.08B | n/a | n/a | n/a | 53.6× | n/a | n/a |
| Hugel 145020.KS | South Korea | $1.69B | -30% | +17% | 38% | 3.6× | -12.1% | +15.0% |
| Alamar Biosciences ALMR | United States | $2.12B | +51% | +195% | -42% | 26.1× | n/a | n/a |
| BGI Genomics 300676.SZ | China | $2.13B | -15% | 0% | -14% | 3.2× | n/a | n/a |